Moderna is proud to be among the many groups working to respond to this continuing global health emergency. This page summarizes key milestones in our work to advance mRNA-1273, our vaccine candidate against the novel coronavirus.
Moderna will apply today to the #US Food and Drug Administration for an authorisation for its coronavirus vaccine.
mRNA-1273 met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study with a vaccine efficacy of 94.5% on November 16th update from the company’s website. Moderna announced a longer shelf life for mRNA-1273 at refrigerated temperatures.
Moderna signed a pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines.
mRNA: A New Approach to Medicine
Using mRNA as a medicine is a fundamentally different approach than treating disease with other drug classes.
It plays a fundamental role in human biology. mRNA is the set of instructions by which cells make all proteins and send them to various parts of the body.
mRNA medicines take advantage of normal biological processes to express proteins and create a desired therapeutic effect. This enables the potential treatment of a broad spectrum of diseases, many of which cannot be addressed with current technologies.
We believe mRNA has the potential to transform how medicines are discovered, developed and manufactured – at a breadth, speed and scale not common in our industry.
